Last edition
News about "Amneal Pharmaceuticals"
Amneal Gets FDA Approval for Epinephrine Vials
The FDA has approved Amneal’s epinephrine injection in both single- and multi-dose vials, strengthening the company’s injectables portfolio with a critical medicine widely used in hospitals for emergency and perioperative care.
Amneal Pharmaceuticals | 10/12/2025 | By Akanki
Amneal Launches BORUZU for Multiple Myeloma and Mantle Cell Lymphoma
BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma.
Amneal Pharmaceuticals | 07/04/2025 | By Aishwarya | 184
Amneal Secures FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Propofol is an intravenous drug commonly used in hospitals for the induction and maintenance of anesthesia and sedation.
Amneal Pharmaceuticals | 21/08/2024 | By Aishwarya | 526
Amneal Pharma Gets US FDA Approval for CREXONT Extended-Release Capsules
CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release (IR) granules and extended-release (ER) pellets.
Amneal Pharmaceuticals | 08/08/2024 | By Aishwarya | 776
Amneal Expands Broad Injectables Portfolio with Addition of Six New Therapies
Amneal Pharmaceuticals has expanded its injectables portfolio with six new injectable product launches during the second quarter of 2024.
Amneal Pharmaceuticals | 11/06/2024 | By Aishwarya | 430
Delegation from HHS and FDA Visit Amneal Manufacturing Site in India
The visit followed the G20 Health Ministers' meeting in Gandhinagar, India, where health ministers from around the world met to discuss global health issues.
Amneal Pharmaceuticals | 01/09/2023 | By Manvi | 954
Amneal Pharma begins commercial operations in India
Appoints Shyamakant Giri as Managing Director and President for India Business and Emerging Markets
Amneal Pharmaceuticals | 10/10/2022 | By Sudeep Soparkar | 1117
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy